News
A tribunal within the US Patent and Trademark Office invalidated several claims of a patent held by AbbVie’s Pharmacyclics, ...
TipRanks on MSN2d
BeiGene Wins Patent Challenge Against PharmacyclicsBeiGene Ltd. announced that the U.S. Patent and Trademark Office has invalidated all claims of a Pharmacyclics LLC patent that were challenged by BeiGene in a post-grant review proceeding. This ...
(NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the U.S. Patent and Trademark Office (USPTO) rendered a ...
SAN CARLOS, Calif. - BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), soon to be known as BeOne Medicines Ltd., has successfully challenged a competitor’s ...
In a report released today, Yaron Werber from TD Cowen maintained a Buy rating on BeiGene (ONC – Research Report), with a price target of ...
Akeso and Summit Therapeutics’ giant-killing, PD-1xVEGF bispecific antibody ivonescimab has posted another phase 3 trial win ...
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the U.S. Patent and Trademark Office ...
In a significant development for BeiGene , Ltd. (NASDAQ:BGNE), a biotechnology company with impressive 54.96% revenue growth over the last twelve months, the U.S. Patent and Trademark Office ...
In a significant development for BeiGene , Ltd. (NASDAQ:BGNE), a biotechnology company with impressive 54.96% revenue growth over the last twelve months, the U.S. Patent and Trademark Office (USPTO) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback